Adaptive Biotechnologies plans to spin out Immune Medicine unit
Adaptive Biotechnologies has announced its intention to separate its Minimal Residual Disease (MRD) diagnostics business from its Immune Medicine discovery unit, saying it expects to identify a preferred structural path by the end of 2026. The Nasdaq-listed company did not specify whether separation would take the form of a sale, spin-out, partnership, or licensing arrangement, and cautioned that no transaction is guaranteed.
The announcement marks the next step in a strategic evolution that began in 2024, when Adaptive restructured MRD and Immune Medicine as distinct operating segments. Chief executive and co-founder Chad Robins said the progress made by both businesses since that reorganisation had reinforced the case for a fuller separation. "We believe this separation is the best way to unlock the full potential of both businesses, increasing their impact on patients and creating long-term value for shareholders," he said.
The MRD business
The MRD division, built around the clonoSEQ platform for detecting trace levels of cancer cells in blood or bone marrow, has grown substantially in recent years. Revenue rose from $103 million in 2023 to $212 million in 2025, and the business reported $15 million in adjusted EBITDA last year on a non-GAAP basis, making it profitable. ClonoSEQ is now integrated into more than 175 electronic medical record systems, covers more than 300 million insured lives, and is active in over 180 biopharma clinical trials. That commercial footprint gives the MRD unit a degree of resilience that is relatively unusual for a diagnostics platform of its age.
Immune Medicine and the strategic rationale
The Immune Medicine business is built on what Adaptive describes as the world's largest clinically linked immune receptor dataset, comprising more than six million functional T-cell receptor and antigen pairs derived from data on more than 10,000 patients. The unit is focused on identifying pathogenic TCRs and the disease-causing antigens they bind, with an emphasis on autoimmune conditions. Adaptive argues that the AI-enhanced discovery capabilities of this platform are better suited to a dedicated structure than to life inside a diagnostics-led commercial organisation.
The logic is familiar in biotech: a profitable diagnostics business and an early-stage drug discovery platform have different capital requirements, valuation frameworks, and investor bases. Keeping them together can dilute the story for both, particularly when the discovery unit needs growth capital that the parent may be reluctant to deploy.
Market context
The MRD testing market is increasingly competitive, with rivals including Guardant Health, Foundation Medicine, and several academic spinouts pursuing next-generation sequencing approaches for haematological cancers. ClonoSEQ's reimbursement position and deep biopharma trial integration are meaningful moats, but maintaining that lead requires continued investment in clinical evidence. Separating out the Immune Medicine unit would free the MRD business to allocate capital more single-mindedly toward that goal.
On the Immune Medicine side, TCR-based drug discovery has attracted significant industry interest. A standalone entity with a clean balance sheet and a focused equity story could be better positioned to attract partnerships with large pharmaceutical companies seeking to bolster their autoimmune pipelines, a sector where deal activity has been elevated over the past two years.
Adaptive has not set a timetable for completing the separation beyond the year-end 2026 target for selecting a preferred path. Investors will be watching for clarity on structure and any indication of third-party interest in the Immune Medicine assets.